首站-论文投稿智能助手
典型文献
National guidelines for diagnosis and treatment of prostate cancer 2022 in China(English version)
文献摘要:
Contents 1.Overview 2.Etiology 2.1 Age and genetic factors 2.2 Exogenous factors 3.Pathological classification and grading system 3.1 Pathological grading and grouping of prostate cancer 3.2 Staging of prostate cancer 3.3 Risk grouping for patients with local or locally advanced prostate cancer 4.Diagnostic evaluation 4.1 Monitoring,screening and early diagnosis 4.2 Genetic testing 4.2.1 Providing genetic counseling and evaluating whether genetic testing is necessary 4.2.2 Treatment decision 4.3 Clinical diagnostic methods 4.3.1 DRE 4.3.2 MRI 4.3.3 Positron emission tomography-CT(PET-CT) 4.3.4 Prostate biopsy 5.Treatment of prostate cancer 5.1 Watchful waiting and active surveillance 5.2 Radical prostatectomy 5.2.1 Low-risk prostate cancer 5.2.2 Intermediate-risk prostate cancer 5.2.3 High-risk prostate cancer 5.2.4 Indications for nerve sparing surgery 5.2.5 PLND 5.2.6 Adjuvant therapy after radical prostatectomy 5.3 External radiotherapy 5.3.1 Indications for radical EBRT 5.3.2 Complications of EBRT for prostate cancer 5.3.3 Surgical treatment of biochemical recurrence after radiotherapy 5.3.4 Current situation and development of radiotherapy technology
文献关键词:
作者姓名:
National Health Commission of the People's Republic of China
作者机构:
引用格式:
[1]National Health Commission of the People's Republic of China-.National guidelines for diagnosis and treatment of prostate cancer 2022 in China(English version))[J].中国癌症研究(英文版),2022(03):270-288
A类:
Watchful
B类:
National,guidelines,diagnosis,treatment,cancer,China,English,version,Contents, 1,Overview, 2,Etiology,Age,genetic,factors,Exogenous, 3,Pathological,classification,grading,system,grouping,Staging,Risk,patients,locally,advanced, 4,Diagnostic,evaluation,Monitoring,screening,early,Genetic,testing,Providing,counseling,evaluating,whether,necessary,Treatment,decision,Clinical,diagnostic,methods,DRE,Positron,emission,tomography,PET,Prostate,biopsy, 5,waiting,active,surveillance,Radical,prostatectomy,Low,risk,Intermediate,High,Indications,nerve,sparing,surgery,PLND,Adjuvant,after,radical,External,radiotherapy,EBRT,Complications,Surgical,biochemical,recurrence,Current,situation,development,technology
AB值:
0.541287
相似文献
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer
Qiong Wang;Zean Li;Jin Yang;Shirong Peng;Qianghua Zhou;Kai Yao;Wenli Cai;Zhongqiu Xie;Fujun Qin;Hui Li;Xu Chen;Kaiwen Li;Hai Huang-Department of Urology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Pathology,School of Medicine,University of Virginia,Charlottesville,VA 22908,USA;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Radiation Oncology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Urology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Department of Radiology,Massachusetts General Hospital,Harvard Medical School,Boston,MA 02114,USA;Department of Urology,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China
Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy
Huan Xu;Junyi Chen;Zhi Cao;Xi Chen;Caihong Huang;Jin Ji;Yalong Xu;Junfeng Jiang;Yue Wang;Guowang Xu;Lina Zhou;Jingyi He;Xuedong Wei;Jason Boyang Wu;Zhong Wang;Shancheng Ren;Fubo Wang-Department of Urology,Shanghai Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Department of Urology,Shanghai Ninth People's Hospital,Shanghai 200011,China;Department of Urology,the Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China;Department of Urology,No.971 Hospital of the People's Liberation Army Navy,Qingdao 266000,China;Center for Genomic and Personalized Medicine,Guangxi Key Laboratory for Genomic and Personalized Medicine,Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine,Guangxi Medical University,Nanning 530021,China;Research Center of Developmental Biology,Second Military Medical University,Shanghai 200433,China;Dalian Institute of Chemical Physics,Chinese Academy of Sciences,Dalian 116023,China;Department of Urology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China;Department of Pharmaceutical Sciences,College of Pharmacy and Pharmaceutical Sciences,Washington State University,Spokane,WA 99202,USA
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。